{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:13Z","timestamp":1790712973179,"version":"4.1.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nitrofurantoin, a broad-spectrum antibiotic available since 1953, is used widely for the treatment of urinary tract infections as it often retains activity against drug-resistant uropathogens. It is contraindicated in pregnant women at term, and in neonates. Like trimethoprim\/sulfamethoxazole, nitrofurantoin carries a warning for patients with known sensitivity to oxidant drugs, notably glucose-6-phosphate dehydrogenase (G6PD) deficiency, in whom it may cause haemolytic anaemia. This is a barrier to uptake in tropical regions where there is a high burden of antimicrobial resistance and where G6PD deficiency is common. Early studies of erythrocyte survival following nitrofurantoin suggest it is less likely to cause oxidant haemolysis in individuals with G6PD deficiency than primaquine. Here we review reports of haemolysis associated with nitrofurantoin from the published literature and from USA (FDA Adverse Event Reporting System; FAERS) and European (VigiBase) pharmacovigilance databases. In total, 318 episodes of haemolytic anaemia were reported and 10 deaths, with 42 (13%) in individuals with confirmed or highly probable G6PD deficiency, out of at least 245 million exposures. A causal link between death and exposure was not reported and a precise risk estimation in G6PD-deficient individuals was not possible as there are few reports from regions where this enzymopathy is most prevalent. The evidence suggests a total daily dose of 200\u2005mg nitrofurantoin may be used for short (3\u20135\u2005day) course urinary tract infection treatment without G6PD screening when accompanied by appropriate advice. Pharmacovigilance in countries with high prevalence of G6PD-deficiency is recommended to monitor for serious adverse events.<\/jats:p>","DOI":"10.1093\/jacamr\/dlac045","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:08:27Z","timestamp":1649934507000},"source":"Crossref","is-referenced-by-count":15,"title":["Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review"],"prefix":"10.1093","volume":"4","author":[{"given":"Judith","family":"Recht","sequence":"first","affiliation":[{"name":"Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University , Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilada","family":"Chansamouth","sequence":"additional","affiliation":[{"name":"Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital , Vientiane, Lao PDR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[{"name":"Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University , Bangkok, Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-4822","authenticated-orcid":false,"given":"Elizabeth A.","family":"Ashley","sequence":"additional","affiliation":[{"name":"Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital , Vientiane, Lao PDR"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"2022072608193887000_dlac045-B1","article-title":"Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations: Review on Antimicrobial Resistance","author":"O\u2019Neill","year":"2014"},{"key":"2022072608193887000_dlac045-B2","article-title":"Tackling Drug-Resistant Infections Globally: final report and recommendations","author":"O\u2019Neill","year":"2016"},{"key":"2022072608193887000_dlac045-B3","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022072608193887000_dlac045-B4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18773\/austprescr.2019.002","article-title":"Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems","volume":"42","author":"Gardiner","year":"2019","journal-title":"Aust Prescr"},{"key":"2022072608193887000_dlac045-B5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fmicb.2014.00551","article-title":"A new strategy to fight antimicrobial resistance: the revival of old antibiotics","volume":"5","author":"Cassir","year":"2014","journal-title":"Front Microbiol"},{"key":"2022072608193887000_dlac045-B6","article-title":"Macrobid\u00ae (nitrofurantoin monohydrate\/macrocrystals) Capsules","author":"FDA","year":"2009"},{"key":"2022072608193887000_dlac045-B7","doi-asserted-by":"crossref","first-page":"106574","DOI":"10.1016\/j.ijantimicag.2022.106574","article-title":"SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","author":"Tutone","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2022072608193887000_dlac045-B8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jac\/dkn222","article-title":"Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli","volume":"62","author":"Sandegren","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2022072608193887000_dlac045-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.03.001","article-title":"Optimizing dosing of nitrofurantoin from a PK\/PD point of view: What do we need to know?","volume":"43","author":"Wijma","year":"2019","journal-title":"Drug Resist Updat"},{"key":"2022072608193887000_dlac045-B10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/B978-0-7020-6285-8.00149-0","volume-title":"Infectious Diseases (Fourth Edition)","author":"Huttner","year":"2017"},{"key":"2022072608193887000_dlac045-B11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4140\/TCP.n.2016.381","article-title":"Updated nitrofurantoin recommendations in the elderly: A closer look at the evidence","volume":"31","author":"Hoang","year":"2016","journal-title":"Consult Pharm"},{"key":"2022072608193887000_dlac045-B12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2022072608193887000_dlac045-B13","article-title":"UTI (lower): antimicrobial prescribing","author":"NICE (National Institute for Health and Care Excellence)","year":"2018"},{"key":"2022072608193887000_dlac045-B14","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/jac\/dky255","article-title":"Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline","volume":"73","author":"Wijma","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"2022072608193887000_dlac045-B15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/33.suppl_A.23","article-title":"Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens","volume":"33","author":"McOsker","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2022072608193887000_dlac045-B16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmi.2016.08.003","article-title":"Nitrofurantoin","volume":"23","author":"Muller","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2022072608193887000_dlac045-B17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.cmi.2020.03.001","article-title":"The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function","volume":"26","author":"Ten Doesschate","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022072608193887000_dlac045-B18","author":"Nifuran New Zealand Data Sheet","year":"2017"},{"key":"2022072608193887000_dlac045-B19","article-title":"Nitrofurantoin","author":"Squadrito","year":"2020"},{"key":"2022072608193887000_dlac045-B20","article-title":"Drugs to Avoid in G6PD deficiency (MIMS Summary Table)"},{"key":"2022072608193887000_dlac045-B21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1177\/106002809002401213","article-title":"Hemolytic reactions to nitrofurantoin in patients with glucose-6-phosphate dehydrogenase deficiency: theory and practice","volume":"24","author":"Gait","year":"1990","journal-title":"DICP"},{"key":"2022072608193887000_dlac045-B22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"key":"2022072608193887000_dlac045-B23","volume-title":"Nathan and Oski's hematology of infancy and childhood, 7th edition","author":"Luzzatto","year":"2009"},{"key":"2022072608193887000_dlac045-B24","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/blood.V84.11.3613.bloodjournal84113613","article-title":"G6PD deficiency","volume":"84","author":"Beutler","year":"1994","journal-title":"Blood"},{"key":"2022072608193887000_dlac045-B25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2019000944","article-title":"Glucose-6-Phosphate Dehydrogenase Deficiency","volume":"136","author":"Luzzatto","year":"2020","journal-title":"Blood"},{"key":"2022072608193887000_dlac045-B26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.2.6046.1227","article-title":"Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency","volume":"2","author":"Chan","year":"1976","journal-title":"Br Med J"},{"key":"2022072608193887000_dlac045-B27","first-page":"884","article-title":"Inhibition of glutathione reductase by nitrofurantoin","volume":"56","author":"Buzard","year":"1960","journal-title":"J Lab Clin Med"},{"key":"2022072608193887000_dlac045-B28","first-page":"1002","article-title":"Nitrofurantoin-induced hemolysis","volume":"62","author":"Powell","year":"1963","journal-title":"J Lab Clin Med"},{"key":"2022072608193887000_dlac045-B29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2007-04-077412","article-title":"Glucose-6-phosphate dehydrogenase deficiency: a historical perspective","volume":"111","author":"Beutler","year":"2008","journal-title":"Blood"},{"key":"2022072608193887000_dlac045-B30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12936-019-2715-0","article-title":"Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030","volume":"18","author":"Ong","year":"2019","journal-title":"Malar J"},{"key":"2022072608193887000_dlac045-B31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4269\/ajtmh.19-0304","article-title":"Bacteremia caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-year study","volume":"102","author":"Chang","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022072608193887000_dlac045-B32","doi-asserted-by":"crossref","first-page":"e007009","DOI":"10.1136\/bmjgh-2021-007009","article-title":"Antimicrobial use and resistance data in human and animal sectors in the Lao PDR: evidence to inform policy","volume":"6","author":"Chansamouth","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2022072608193887000_dlac045-B33","first-page":"540","article-title":"Nitrofurantoin","volume":"19","author":"D\u2019Arcy","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"2022072608193887000_dlac045-B34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-64-4-817","article-title":"Clinical spectrum of hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency","volume":"64","author":"Burka","year":"1966","journal-title":"Ann Intern Med"},{"key":"2022072608193887000_dlac045-B35","first-page":"684","volume-title":"Drugs, Chemicals, and Blood Dyscrasias: A Summary of Blood Abnormalities Associated with Exposure to Specific Drugs and Chemicals","author":"Swanson","year":"1977"},{"key":"2022072608193887000_dlac045-B36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0002-9378(67)90172-X","article-title":"Treatment of pyelonephritis in pregnancy","volume":"98","author":"Hibbard","year":"1967","journal-title":"Am J Obstet Gynecol"},{"key":"2022072608193887000_dlac045-B37","first-page":"340","article-title":"Overt hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency: a survey in general practice","volume":"11","author":"Herman","year":"1975","journal-title":"Isr J Med Sci"},{"key":"2022072608193887000_dlac045-B38","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022072608193887000_dlac045-B39","doi-asserted-by":"crossref","first-page":"bcr2013010087","DOI":"10.1136\/bcr-2013-010087","article-title":"Haemolytic anaemia after nitrofurantoin treatment in a pregnant woman with G6PD deficiency","volume":"2014","author":"van de Mheen","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2022072608193887000_dlac045-B40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3949\/ccjm.80a.120061","article-title":"Dyspnea after treatment of recurrent urinary tract infection","volume":"80","author":"Ghimire","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"2022072608193887000_dlac045-B41","article-title":"AMARYL\u00ae (glimepiride tablets)","author":"FDA","year":"2009"},{"key":"2022072608193887000_dlac045-B42","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Nitrofurantoin","year":"2012"},{"key":"2022072608193887000_dlac045-B43","article-title":"Drug Usage Statistics, United States, 2007-2017. Nitrofurantoin"},{"key":"2022072608193887000_dlac045-B44","article-title":"Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) CIPARS \u2013 Human Antimicrobial Use Short Report, 2000\u20132009","author":"GovernementCanada","year":"2011"},{"key":"2022072608193887000_dlac045-B45","article-title":"Chapter 2: Human Antimicrobial Drug Use Report 2012\/2013 \u2013 Pharmacy dispensation data","author":"GovernementCanada","year":"2015"},{"key":"2022072608193887000_dlac045-B46","article-title":"Population estimates on July 1st, by age and sex","author":"StatisticsCanada","year":"2020"},{"key":"2022072608193887000_dlac045-B47","article-title":"Update on Nitrofurantoin Use in Renal Impairment, Medicines Adverse Reactions Committee","author":"NewZealandMedSafe","year":"2019"},{"key":"2022072608193887000_dlac045-B48","article-title":"Australian Adverse Drug Reactions Bulletin, Vol 27, No 3"},{"key":"2022072608193887000_dlac045-B49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eclinm.2019.07.012","article-title":"Lower Urinary Tract Infections: Management. Outcomes and Risk Factors for Antibiotic Re-prescription in Primary Care","volume":"14","author":"Pujades-Rodriguez","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2022072608193887000_dlac045-B50","article-title":"Leading ten antibacterial drugs dispensed in England in 2019, by number of items","year":"2020"},{"key":"2022072608193887000_dlac045-B51","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/jac\/dkx504","article-title":"Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions?","volume":"73","author":"Dolk","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022072608193887000_dlac045-B52","article-title":"Safety of 8-aminoquinoline antimalarial medicines","author":"Recht","year":"2014"},{"key":"2022072608193887000_dlac045-B53","first-page":"601","article-title":"Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group","volume":"67","year":"1989","journal-title":"Bull World Health Organ"},{"key":"2022072608193887000_dlac045-B54","doi-asserted-by":"crossref","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med"},{"issue":"Suppl 1A","key":"2022072608193887000_dlac045-B55","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"113","author":"Foxman","year":"2002","journal-title":"Am J Med"},{"key":"2022072608193887000_dlac045-B56","article-title":"Nitrofurantoina (Furantoina\u00ae): nuevas restricciones de uso (emitido por la agencia espa\u00f1ola de medicamentos y productos sanitariosAEMPS)","author":"AEMPS","year":"2016"},{"key":"2022072608193887000_dlac045-B57","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/cpt.1720","article-title":"Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements","volume":"107","author":"Shekhani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2022072608193887000_dlac045-B58","first-page":"224","article-title":"Estudio de utilizaci\u00f3n de antibi\u00f3ticos en el servicio de consulta externa de un hospital de tercer nivel de la ciudad de Bogot\u00e1","volume":"37","author":"L\u00f3pez Guti\u00e9rrez","year":"2008","journal-title":"Revista Colombiana de Ciencias Qu\u00edmico - Farmac\u00e9uticas"},{"key":"2022072608193887000_dlac045-B59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-92-1-14","article-title":"Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin","volume":"92","author":"Sharp","year":"1980","journal-title":"Ann Intern Med"},{"key":"2022072608193887000_dlac045-B60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bjh.12665","article-title":"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","volume":"164","author":"Luzzatto","year":"2014","journal-title":"Br J Haematol"},{"key":"2022072608193887000_dlac045-B61","article-title":"The WHO Essential Medicines List Antibiotic Book","author":"WHO","year":"2021"},{"key":"2022072608193887000_dlac045-B62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1956.72970240001008","article-title":"Hemolytic anemia in patient receiving nitrofurantoin (furadantin)","volume":"162","author":"West","year":"1956","journal-title":"J Am Med Assoc"},{"key":"2022072608193887000_dlac045-B63","first-page":"245","article-title":"Mechanism of the hemolytic anemia induced by nitrofurantoin (furadantin); further observations on the incidence and significance of primaquine-sensitive red cells","volume":"101","author":"Kimbro","year":"1957","journal-title":"Bull Johns Hopkins Hosp"},{"key":"2022072608193887000_dlac045-B64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/adc.33.172.527","article-title":"Haemolytic anaemia in a child receiving nitrofurantoin","volume":"33","author":"Levy","year":"1958","journal-title":"Arch Dis Child"},{"key":"2022072608193887000_dlac045-B65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jama.1963.03060040070024","article-title":"Drug-associated blood dyscrasias. Recent additions to the Registry","volume":"185","author":"Best","year":"1963","journal-title":"JAMA"},{"key":"2022072608193887000_dlac045-B66","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1471-0528.1963.tb15057.x","article-title":"Urinary antiseptics causing haemolytic anaemia in pregnancy in a West Indian woman with red cell enzyme deficiency","volume":"70","author":"Garrett","year":"1963","journal-title":"J Obstet Gynaecol Br Commonw"},{"key":"2022072608193887000_dlac045-B67","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(64)92524-3","article-title":"Nitrofurantoin and megaloblastic anaemia","volume":"2","author":"Deveber","year":"1964","journal-title":"Lancet"},{"key":"2022072608193887000_dlac045-B68","first-page":"939","article-title":"[Acute Hemolytic Anemia Caused by Nitrofurantoin in an Iranian Woman Presenting an Erythrocyte Glucose-6-Phosphate-Dehydrogenase Deficiency; Demonstration of the Heterozygosis of the Patient by an Original Method]","volume":"94","author":"Jeannet","year":"1964","journal-title":"Schweiz Med Wochenschr"},{"key":"2022072608193887000_dlac045-B69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jama.1965.03090170135030","article-title":"Severe anemia with hemolysis and megaloblastic erythropoiesis. A reaction to nitrofurantoin administered during pregnancy","volume":"194","author":"Pritchard","year":"1965","journal-title":"JAMA"},{"key":"2022072608193887000_dlac045-B70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.me.18.020167.000415","article-title":"Drug-induced hemolysis","volume":"18","author":"Dausset","year":"1967","journal-title":"Annu Rev Med"},{"key":"2022072608193887000_dlac045-B71","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archneur.1968.00470360102010","article-title":"Neural effects of nitrofurantoin","volume":"18","author":"Toole","year":"1968","journal-title":"Arch Neurol"},{"key":"2022072608193887000_dlac045-B72","first-page":"1793","article-title":"[A case of drug-induced hemolytic anemia with methemoglobinemia in a newborn]","volume":"22","author":"Maszkiewicz","year":"1969","journal-title":"Wiad Lek"},{"key":"2022072608193887000_dlac045-B73","first-page":"483","article-title":"Glutathione stability of red cells\u2013observations on a sample from Agra","volume":"23","author":"Mital","year":"1969","journal-title":"Indian J Med Sci"},{"key":"2022072608193887000_dlac045-B74","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archinte.1970.00310020108013","article-title":"Acute hemolytic anemia associated with erythrocyte glutathione-peroxidase deficiency","volume":"125","author":"Steinberg","year":"1970","journal-title":"Arch Intern Med"},{"key":"2022072608193887000_dlac045-B75","first-page":"49","article-title":"Hemolysis induced by nitrofurantoin","volume":"73","author":"Carpel","year":"1970","journal-title":"Pa Med"},{"key":"2022072608193887000_dlac045-B76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1971.00310210075006","article-title":"Adverse reactions to sulfisoxazole, sulfamethoxazole, and nitrofurantoin. Manifestations and specific reaction rates during 2,118 courses of therapy","volume":"128","author":"Koch-Weser","year":"1971","journal-title":"Arch Intern Med"},{"key":"2022072608193887000_dlac045-B77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ajcp\/58.5.408","article-title":"Chronic hemolytic anemia associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin","volume":"58","author":"Stefanini","year":"1972","journal-title":"Am J Clin Pathol"},{"key":"2022072608193887000_dlac045-B78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jama.1974.03240010045029","article-title":"Adverse reactions to antimicrobial agents","volume":"230","author":"Caldwell","year":"1974","journal-title":"JAMA"},{"key":"2022072608193887000_dlac045-B79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00000441-197609000-00010","article-title":"Hyperlactatemia and hemolysis in G6PD deficiency after nitrofurantoin ingestion","volume":"272","author":"Lavelle","year":"1976","journal-title":"Am J Med Sci"},{"key":"2022072608193887000_dlac045-B80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0929-693X(00)80155-4","article-title":"[Hemolytic anemia in a newborn after maternal treatment with nitrofurantoin at the end of pregnancy]","volume":"7","author":"Bruel","year":"2000","journal-title":"Arch Pediatr"},{"issue":"Suppl 1","key":"2022072608193887000_dlac045-B81","first-page":"S295","article-title":"Acute anemia after a urinary tract infection (UTI): A case of hemolytic anemia in a newly diagnosed glucose-6-phosphate dehydrogenase (G6PD) deficient patient (abstract from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego, CA, USA)","volume":"29","author":"Nasir","year":"2014","journal-title":"J Gen Int Med"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/3\/dlac045\/45065074\/dlac045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/3\/dlac045\/45065074\/dlac045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:20:56Z","timestamp":1658823656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlac045\/6577338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlac045","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,5,3]]},"article-number":"dlac045"}}